Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study-Reference-Cited by-同舟云学术

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Published:2021-08 Issue:8 Volume:22 Page:1115-1125
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gafita Andrei,Calais Jeremie,Grogan Tristan R,Hadaschik Boris,Wang Hui,Weber Manuel,Sandhu Shahneen,Kratochwil Clemens,Esfandiari Rouzbeh,Tauber Robert,Zeldin Anna,Rathke Hendrik,Armstrong Wesley R,Robertson Andrew,Thin Pan,D'Alessandria Calogero,Rettig Matthew B,Delpassand Ebrahim S,Haberkorn Uwe,Elashoff David,Herrmann Ken,Czernin Johannes,Hofman Michael S,Fendler Wolfgang P,Eiber Matthias

Funder

Prostate Cancer Foundation

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study;Hofman;Lancet Oncol,2018

2. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer;Heck;Eur Urol,2019

3. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial;Hofman;Lancet,2021

4. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer;Sartor;N Engl J Med,2021

5. Novel therapies are changing treatment paradigms in metastatic prostate cancer;Powers;J Hematol Oncol,2020

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy;Nuklearmedizin - NuclearMedicine;2024-09-03

2. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study;The Lancet Oncology;2024-09

3. Predicting the risk category of thymoma with machine learning-based computed tomography radiomics signatures and their between-imaging phase differences;Scientific Reports;2024-08-19

4. Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial);Radiology;2024-08-01

5. Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival;Cancers;2024-07-26